热门站点| 世界资料网 | 专利资料网 | 世界资料网论坛
收藏本站| 设为首页| 首页

印发广东省地方税务系统经费管理办法的通知

作者:法律资料网 时间:2024-07-12 17:29:24  浏览:9533   来源:法律资料网
下载地址: 点击此处下载

印发广东省地方税务系统经费管理办法的通知

广东省人民政府办公厅


粤府办〔2005〕106号
━━━━━━━━━━━━━━━━━━━━━━━━━━━
印发广东省地方税务系统经费管理办法的通知

各地级以上市人民政府,各县(市、区)人民政府,省政府各部门、各直属机构:
  《广东省地方税务系统经费管理办法》业经省人民政府同意,现印发给你们,请认真贯彻执行。执行中遇到的问题,请径向省财政厅和省地税局反映。


广东省人民政府办公厅
二○○五年十二月二十七日  






广东省地方税务系统经费管理办法

  为进一步规范全省地税系统(不含深圳)经费管理,保障各级地税机关正常运转和我省地税事业不断发展,根据《国务院关于地方税务机构管理体制问题的通知》(国发〔1997〕34号)、《印发广东省地方税务系统经费管理暂行办法的通知》(粤府〔1999〕14号)和《关于印发广东省省级单位部门预算试行办法的通知》(粤财预〔2002〕105号)的有关规定,结合我省财税体制的实际,制定本办法。

  一、经费核定原则
  (一)双重管理和分级合理负担的原则。地税系统经费管理体制要体现上级地税机关和地方政府的双重管理,适应分级财政管理体制,由各级财政合理负担。
  (二)税收成本和公平效率兼顾的原则。既遵循税收成本规律,又体现政府管理部门之间公平效率原则,建立与税收征管要求相适应的地税系统经费管理体制。
  (三)基本保障和协调发展的原则。省级经费和市县经费既统一保障地税系统基本支出和项目支出的需要,又相对规范不同的支出范畴,以保障地区间财税事业协调发展。
  (四)规范管理和激励相结合的原则。逐步按照部门预算要求,规范基本支出标准,加强项目支出管理;征收经费核定比例适当降低;引入激励机制。

  二、分类核定经费
  (一)经费来源。
  各级地税经费由上级返还上划经费基数、上级项目补助经费和地税部门当年征收缴入本级地方库的税费(不含社保费)收入按比例核定的征收经费以及其他渠道安排的经费组成。
  (二)经费支出。
  地税经费支出按基本支出和项目支出分类管理。
  基本支出是指地税机关为保障其机构正常运转和完成其日常工作任务所必须的支出,包括人员支出、日常公用支出及对个人和家庭的补助支出。
  项目支出是指地税机关为完成特定行政工作任务或事业发展而发生的支出,包括行政事业性支出中的大型会议、大型修缮、基本建设、其他行政事业性项目等支出。
  (三)省级经费。
  为鼓励地税部门在完成年度税收收入任务的基础上,实现一定的超收,省级征收经费核定办法引入激励机制,根据省地税局完成年度预算任务收入和超年度预算任务收入分别核定。2005-2007年年度预算任务收入分别按3%、2.8%、2.6%的比例核定征收经费;超年度预算任务部分按3.8%的比例核定征收经费。
  省级征收经费(含省级税收代征代扣代缴手续费支出)按轻重缓急原则安排全省地税系统项目支出。
  省地税局经费纳入省级部门预算管理。
  (四)市县级经费。
  市县级经费由省分档次分类核定。各市县执行的具体比例,由当地财政部门和地税部门共同商定。新的核定比例要比原比例有所下降,且不得超出省核定的该档次最高比例。
  一类:广州,按2%-2.3%核定(其中增城、从化按2%-2.5%核定);
  二类:珠海、佛山、东莞、中山、江门市,按2.5%-5%核定;
  三类:汕头、惠州、湛江、茂名市,按4.5%-7.5%核定;
  四类:韶关、河源、梅州、汕尾、阳江、肇庆、清远、潮州、揭阳、云浮市,按6%-9.5%核定。
  市县级经费应首先保证地税部门基本支出安排,再根据需要和可能安排本级项目支出。其中,基建支出按照分级负担的原则由各市县视财力情况解决,纳入地方政府的基建计划统筹安排。

  三、经费支出安排
  各级地税征收经费按计划列入本级财政预算安排,按进度拨给地税部门使用,年终清算。
  (一)省级项目支出。
  省级项目支出主要包括省级代征代扣代缴手续费、全省信息化建设(包括系统开发、维护、数据处理以及装备和设备更新、购置等)、票证印制、基层基建补助、纳税服务、征管业务费(含发票抽奖等)和系统培训、税收宣传、稽查办案等。
  省地税局每年在编制经费预算时向省财政厅申报具体项目经费,按程序审批后,由省财政厅按项目进度拨付省地税局,由省地税局拨付各级税务机关使用。
  (二)市县级经费支出。
  市县征收经费应首先安排本级基本支出,保障人员经费、日常公用经费及个人和家庭补助支出,再在经费总额内统筹安排本级项目经费。
  1.基本支出安排。省每年将地税部门1998年上划基数通过省地税局返拨各市,各级财政部门结合本级经费,合理安排本级地税部门全年的基本支出。人员及日常公用经费标准参照当地行政或公检法部门的支出水平制定。
  2.项目经费的安排。原则上全省性的项目经费由省级税务经费安排,地方性的项目经费由本级税务经费安排。
  市县级地税经费支出(基本支出和地方性项目支出)实行预算制,市县地税部门应编制部门预算,纳入同级财政预算管理,并报上级主管部门备案。项目经费管理办法由省地税局另行制定。

  四、其他问题
  (一)社保费征收经费、社会保险、医疗和住房补贴经费按原渠道解决。
  (二)各级收入不得重复核定征收经费和其他各项经费。各级地税部门委托其他部门征收的税费收入,其代征代扣手续费由税务征收经费安排解决。

  五、监督管理
  (一)各级财政和地税部门应严格按规定核拨各项经费,不得以退库、截留等形式提取。
  (二)各项经费应专款专用。
  (三)各级地税部门要按规定编制有关报表资料,每年要对本部门的经费使用情况进行自查评估,报送同级财政、审计部门和上级主管部门,自觉接受财政、审计和上级主管部门的监督。

  六、本办法自2005年1月1日起执行,暂定3年。

  七、本办法由省财政厅和省地税局负责解释。


下载地址: 点击此处下载

深圳市旅行社“四统一”管理实施办法

广东省深圳市旅游局


深圳市旅游局
关于印发《深圳市旅行社“四统一”
管理实施办法》的通知
(2004年2月25日)

深旅行管〔2004〕24号

  为促进我市旅行社依法规范经营,提高旅游服务质量,根据国务院《旅行社管理条例》和国家旅游局《旅行社管理条例实施细则》的有关规定,结合我市实际情况,我局制定了《深圳市旅行社“四统一”管理实施办法》。现予印发,请遵照执行。

深圳市旅行社“四统一”管理实施办法

  第一条 为促进旅行社依法规范经营,提高旅游服务质量,根据《旅行社管理条例》和《旅行社管理条例实施细则》的有关规定,制定本办法。
  第二条 本办法适用于在我市依法设立的各类旅行社。
  第三条 本办法所称“四统一”管理,是指旅行社与其内设业务部门和营业部(以下简称业务部门)必须实行统一管理、统一财务、统一招徕、统一接待,不得以承包、挂靠或变相承包、挂靠方式非法转让全部或部分经营权。
  第四条 统一管理的主要内容如下:
  (一)业务部门负责人应当是旅行社正式聘用的员工,并持有旅行社经理资格证书;
  (二)旅行社应当实行统一的人事管理制度,业务部门用工由旅行社统一聘用并签订劳动合同,员工档案由旅行社统一建立和管理;
  (三)业务部门员工工资、福利由旅行社统一支付,参加法定社会保险费用由旅行社统一缴纳;
  (四)业务部门营业场所、办公用品和经营设施由旅行社统一租赁或购置;
  (五)旅行社及其业务部门应当使用统一标识和品牌;
  (六)旅行社及其业务部门应当建立健全规章制度;
  (七)业务部门的业务范围应当限定为旅游招徕、宣传和咨询,但负责旅行社总部业务具体运作的部门除外;
  (八)具备条件的旅行社对其业务部门应当实行电脑联网管理;
  (九)旅行社及其业务部门应当在营业场所显著位置设置旅游投诉电话号码牌及游客提示牌,提醒旅游者签订旅游合同、索取正式发票。
  第五条 统一财务的主要内容如下:
  (一)旅行社及其业务部门应当使用统一的税务发票、收据和书面合同;
  (二)旅行社应当对其业务部门使用的发票、收据、书面合同、印章等进行统一管理;
  (三)业务部门财务人员由旅行社委派,直接对旅行社负责。业务部门的资金调用和团款结算由旅行社统一进行。
  第六条 统一招徕的主要内容如下:
  (一)旅游产品应当由旅行社统一设计策划,业务部门不得自行推出产品;
  (二)旅游产品价格由旅行社统一制定,业务部门不得自行制定产品价格;
  (三)宣传促销活动由旅行社统一安排,业务部门不得自行发布旅游广告或自制宣传资料。
  第七条 统一接待的主要内容如下:
  (一)业务部门招收的游客应当由旅行社统一安排,业务部门不得自行出团或拼团;
  (二)旅游团队的计划与调配以及团队导游、领队等应当由旅行社统一操作与安排;
  (三)旅行社与旅游供应商及其他旅行社之间的业务合同应当由旅行社统一签订。
  第八条 各旅行社及其业务部门应当严格遵守以上规定。对于违反“四统一”管理规定的旅行社,市旅游主管部门将按《旅行社管理条例》和《旅行社管理条例实施细则》的有关规定予以处罚。
  第九条 本办法自2004年3月1日起执行。

Provisions for Supervision of Drug Distribution

Commissioner of SFDA


Provisions for Supervision of Drug Distribution



(SFDA Decree No.26)

The Provisions for Supervision of Drug Distribution, adopted at the executive meeting of the State Food and Drug Administration on December 8, 2006, is hereby promulgated and shall go into effect as of May 1, 2007.


Shao Mingli
Commissioner of SFDA
January 31, 2007





Provisions for Supervision of Drug Distribution


Chapter I

Article 1 These Provisions are formulated for the purposes of strengthening drug supervision, regulating drug distribution order and ensuring drug quality in accordance with the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China (hereinafter referred to as Regulations for Implementation of the Drug Administration Law) and the requirements of the relevant law and regulations.

Article 2 Any institutions or individuals engaged in the purchase, sales and supervision of drugs in the People’s Republic of China shall abide by the Provisions.

Article 3 Drug manufacturers, distributors and medical institutions shall be responsible for the quality of the drugs that they produce, distribute or use.

Drug manufacturers and distributors shall carry out reforms and innovations in the direction of pharmaceutical logistics provided that drug quality is assured.

Article 4 The drug regulatory departments encourage individuals and organizations to involve in the social supervision on drug distribution. Individuals or organizations have the right to report or accuse of any violation of the Provisions to the drug regulatory departments.


Chapter II Supervision on Drug Purchase and Sales by Manufacturers and Distributors

Article 5 Drug manufacturers or distributors shall be responsible for their drug purchases and sales, and liable for the purchases and sales activities of their sales staff or offices in the name of their enterprise.

Article 6 Drug manufacturers or distributors shall train their purchase and sales staff on drug related laws, regulations and professional knowledge, and establish training records including time, venue, content and trainees.

Article 7 Drug manufacturers or distributors shall strengthen the management of the sales staff and set up specific rules for their sales behaviors.

Article 8 Drug manufacturers or distributors shall not store or spot trade drugs on the premises not approved by the drug regulatory departments.

Article 9 Drug manufacturers shall sell drugs that they produce in the name of themselves, and shall not sell any drug that they produce for contract manufacturing or any drugs produced by others.

Article 10 Where a drug manufacturer or wholesaler sells drugs, it shall provide the following materials:
(1) Copies of the Drug Manufacturing Certificate or Drug Supply Certificate, stamped with the seal of the enterprise, and the business license;
(2) Copies of the approval documents for the drug to be sold, stamped with the seal of the enterprise ;
(3) For import drug sales, relevant proof documents should be provided in accordance with the related provisions of the State.

Where a drug manufacturer or wholesaler sends any of its sales staff to sell drugs, it shall, in addition to the materials prescribed in the previous paragraph of this Article, provide a copy of the authorization letter with the seal of the enterprise. The original authorization letter shall contain the authorized drugs, regions and time of validity for drug sales, indicate the identity card numbers of the sales staff, and be stamped with the enterprise seal and legal representative seal (or signature). The sales staff shall show the original authorization letter and identity card for the check by drug purchasers.

Article 11 Where a drug manufacturer or wholesaler sells drugs, it shall provide sales document indicating supplier’s name, drug name, manufacturer, batch number, quantity, price, etc.

Where a drug retailer sells drugs, it shall provide sales document indicating drug name, manufacturer, quantity, price, batch number, etc.

Article 12 Where a drug manufacturer or distributor purchases drugs, it shall request, examine and retain the relevant certificates and documents of the supplier in accordance with the requirements set forth in Article 10 of the Provisions, and request and retain sales document in accordance with the requirements set forth in Article 11 of the Provisions.

The documents retained by the drug manufacturer or distributor in accordance with the previous paragraph of this Article shall be kept till one year after the date of expiry, but not less than three years.

Article 13 Where a drug manufacturer or distributor knows or should know that any person without certificates produces or distributes drugs, it shall not provide the person with any drug.

Article 14 A drug manufacturer or distributor shall not provide premises, qualifications documents, notes, etc. as conveniences for others to distribute drugs in its own name.

Article 15 A drug manufacturer or distributor shall not spot trade drugs by means of exhibition, exposition, trade fair, commodity fair or product promotion event.

Article 16 A drug distributor shall not purchase or sell pharmaceutical preparations prepared by medical institutions.

Article 17 A drug distributor shall not change its distribution mode without approval of the drug regulatory department.

A drug distributor shall operate within the approved distribution scope in the Drug Supply Certificate.

Article 18 A drug retailer shall, pursuant to the requirements of drug classification regulations set forth by the State Food and Drug Administration, sell prescription drugs in the presence of prescriptions.

Any drug retailer selling prescription drugs or Class A non-prescription drugs shall, in the absence of its licensed pharmacists and other qualified pharmaceutical professionals, put up a public notice and stop selling prescription drugs and Class A non-prescription drugs.

Article 19 For drugs that need low-temperature or cold storage as specified in drug insert sheets, the drug manufacturer or distributor shall transport and store the drugs with low-temperature or cold storage facilities in accordance with the relevant provisions.

When finding any drug manufacturer or distributor violates the requirements in the previous paragraph of this article, the drug regulatory department shall seal up or seize the drugs concerned immediately and deal with the matter in accordance with law.

Article 20 A drug manufacturer or distributor shall not provide the public with prescription drug or Class A non-prescription drug by means of tie-in sale, offering free drugs in association with sales of drug or commodity sale, etc.

Article 21 A drug manufacturer or distributor shall not sell prescription drugs directly to the public by post or over internet.

Article 22 Any illegal purchase of drugs is prohibited.


Chapter III Supervision on Drug Purchase and Storage by Medical Institutions

Article 23 The pharmacy established by a medical institution shall have the premise, equipment, storage facilities, hygienic environment, and pharmaceutical professionals required for drug dispensing. It shall also have the drug quality control units or personnel, and establish a system for drug storage.

Article 24 Where a medical insititution purchases drugs, it shall request, examine and retain the relevant certificates, documents and notes of the supplier in accordance with the requirements set forth in Article 12 of the Provisions.

Article 25 Where a medical institution purchases drugs, it shall establish and apply an examination and acceptance system, and keep authentic and complete purchase records. Purchase records shall indicate the adopted name of the drug in China, manufacturer (for Chinese crude drug, the origin should be noted), dosage form, date of expiry, drug approval number, supplier, quantity, price and date of purchase.

Drug purchase records shall be kept till one year after the date of expiry, but not less than three years.

Article 26 A medical institution shall establish and apply a system for drug storage and maintenance, and take necessary measures to ensure drug quality, such as cold storage, protection against freeze and humidity, ventilation, moisture proof, protection from direct light and fire, and avoidance of insects and rodents.

A medical institution shall store drugs and non-drug products separately; Chinese crude drugs, prepared slices of Chinese crude drugs, pharmaceuticals, and traditional Chinese medicine preparations shall be stored separately by category.

Article 27 A medical institution or family planning technical service institution shall not directly provide drugs for patients without diagnosis or treatment.

Article 28 A medical institution shall not sell prescription drugs directly to the public by post or over internet.

Article 29 Where a medical institution purchases drugs via a centralized tendering, it shall comply with the relevant requirements of the Drug Administration Law, Regulations for Implementation of the Drug Administration Law and the Provisions.


Chapter IV Legal Liabilities

Article 30 In any of the following circumstances, the drug manufacturer or distributor shall be instructed to rectify within a time limit and given a disciplinary warning; and if the drug manufacturer or distributor fails to do so, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan:
(1) any drug manufacturer or distributor in violation of Article 6 of the Provisions;
(2) any drug manufacturer or wholesaler in violation of the first paragraph of Article 11 of the Provisions;
(3) any drug manufacturer or distributor, in violation of Article 12 of the Provisions, failing to keep the relevant documents as required.

Article 31 Any drug manufacturer or distributor in violation of Article 7 of the Provisions shall be given a disciplinary warning and instructed to rectify within a time limit.

Article 32 In accordance with the provisions in Article 73 of the Drug Administration Law, in any of the following circumstances, the drugs illegally sold and the illegal gains therefrom shall be confiscated, and the drug manufacturer or distributor shall be fined not less than two times but not more than five times the value of the drugs illegally sold:
(1) any drug manufacturer or distributor, in violation of Article 8 of the Provisions, spot trading drugs on the premises not approved by the drug regulatory departments.
(2) any drug manufacturer in violation of Article 9 of the Provisions;
(3) any drug manufacturer or distributor in violation of Article 15 of the Provisions;
(4) any drug distributor in violation of Article 17 of the Provisions.

Article 33 Any drug manufacturer or distributor, in violation of Article 8 of the Provisions, storing drugs on the premises not approved by the drug regulatory departments,shall be punished pursuant to the provisions in Article 74 of the Regulations for Implementation of the Drug Administration Law.

Article 34 Any drug retailer in violation of the provisions in the second paragraph of Article 11 of the Provisions shall be instructed to rectify and given a disciplinary warning; and if the drug retailer fails to do so within a time limit, it shall be fined not more than RMB 500 yuan.

Article 35 Where a drug manufacturer or distributor, in violation of Article 13 of the Provisions, knows or should know that any person without certificates produces or distributes drugs, but still provide the person with drugs, they shall be given a disciplinary warning, instructed to rectify and fined not more than RMB 10,000 yuan. If the circumstances are serious, they shall be fined not less than RMB 10,000 yuan but not more than RMB 30,000 yuan.

Article 36 Drug manufacturers and distributors in violation of Article 14 of the Provisions shall be punished pursuant to the provisions in Article 82 of the Drug Administration Law.

Article 37 Where a drug distributor, in violation of Article 16 of the Provisions, purchases or sells pharmaceutical preparations dispensed by medical institutions, it shall be punished pursuant to the provisions in Article 80 of the Drug Administration Law.

Article 38 Any drug retailer in violation of the first paragraph of Article 18 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so or the circumstances are serious, it shall be fined not more than RMB 1,000 yuan.

Where a drug retailer, in violation of the second paragraph of Article 18 of the Provisions, sells prescription drugs or Class A non-prescription drugs in absence of licensed pharmacists or other qualified pharmaceutical professionals, it shall be instructed to rectify within a time limit and given a disciplinary warning; if it fails to do so, it shall be fined not more than RMB 1,000 yuan.

Article 39 Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to transport drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be given a disciplinary warning and instructed to rectify within a time limit; if it fails to do as instructed, it shall be fined not less than RMB 5,000 yuan but not more than RMB 20,000 yuan. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.

Where a drug manufacturer or wholesaler, in violation of Article 19 of the Provisions, fails to store drugs under low-temperature or cold storage conditions as specified in insert sheets, it shall be punished pursuant to the provisions in Article 79 of the Drug Administration Law. Where the drugs concerned are legally proved to be counterfeit or substandard drugs, the drug manufacturer or wholesaler shall be punished in accordance with the relevant provisions of the Drug Administration Law.

Article 40 Any drug manufacturer or distributor in violation of Article 20 of the Provisions shall be instructed to rectify within a time limit and given a disciplinary warning; if the drug manufacturer or distributor fails to do so or the circumstances are serious, they shall be fined not more than two times the value of the free drugs offered, but not more than RMB 30,000 yuan.

Article 41 Any institution, in violation of Article 23 to Article 27 of the Provisions, shall be instructed to rectify within a time limit; if the circumstances are serious, it shall be announced.

Article 42 Where a drug manufacturer or distributor in violation of Article 21 of the Provisions or a medical institution in violation of Article 28 of the Provisions sells prescription drugs directly to the public by post, over internet, etc., they shall be instructed to rectify, given a disciplinary warning, and fined not more than two times the value of the drugs sold, but not more than RMB 30,000 yuan.

Article 43 Any illegal purchase of drugs, in violation of Article 22 of the Provisions, shall be punished pursuant to the provisions in Article 73 of the Drug Administration Law.

Article 44 Where a drug regulatory department or its staff that neglects its duty fails to stop or punish illegal activities that should be stopped or punished, administrative sanctions shall be imposed to the person directly in charge and other persons directly responsible. If a crime is constituted, criminal liabilities shall be investigated in accordance with law.


Chapter V Supplementary Provisions

Article 45 Spot trading of drugs in the Provisions refers to the activity that drug manufacturers, distributors or their appointed sales staff carry and sell drugs to unspecified objects on spot other than the premises approved by the drug regulatory departments.

Article 46 With respect to the supervision on the distribution of specially controlled drugs, vaccines, and military medicines, if otherwise provided by the relevant laws, regulations and provisions, they shall prevail.

Article 47 The Provisions shall come into force as of May 1, 2007. As of the date when the Provisions goes into effect, the Provisions for Supervision of Drug Distribution (Interim) (SFDA Decree No.7) implemented on August 1, 1999 shall be annulled therefrom.





版权声明:所有资料均为作者提供或网友推荐收集整理而来,仅供爱好者学习和研究使用,版权归原作者所有。
如本站内容有侵犯您的合法权益,请和我们取得联系,我们将立即改正或删除。
京ICP备14017250号-1